Description
A PDE9 inhibitor and adenosine A1 and A2 receptor antagonist (Kis = 35 and 22 μM, respectively in equine forebrain tissues); is the main metabolite of caffeine in humans; increases locomotor activity and counteracts adenosine receptor agonist-induced motor depression in rats not habituated to caffeine; induces a significant increase in striatal cGMP and extracellular striatal dopamine concentrations in vivo; promotes wakefulness and increases locomotor activity and core temperature in narcoleptic transgenic mice without increasing behavioral anxiety,
Formal name: 3,7-dihydro-1,7-dimethyl-1H-purine-2,6-dione
Synonyms: 1,7-Dimethylxanthine|NSC 400018
Molecular weight: 180.2
CAS: 611-59-6
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Product Type|Biochemicals|Small Molecule Inhibitors|Phosphodiesterases||Research Area|Cell Biology|Cell Signaling|cGMP Signaling||Research Area|Neuroscience|Behavioral Neuroscience|Sleep & Biological Rhythms||Research Area|Toxicology|Drug Metabolism|Drug Metabolites